[Federal Register: October 2, 2006 (Volume 71, Number 190)]
[Proposed Rules]
[Page 57892-57893]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr02oc06-16]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
21 CFR Parts 20, 25, 201, 202, 207, 225, 226, 500, 510, 511, 515,
516, 558, and 589
[Docket No. 2006N-0067]
RIN 0910-AF67
Index of Legally Marketed Unapproved New Animal Drugs for Minor
Species; Extension of Comment Period
AGENCY: Food and Drug Administration, HHS.
ACTION: Proposed rule; extension of comment period.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is extending to
December 20, 2006, the comment period for the proposed rule that
appeared in the Federal Register of August 22, 2006 (71 FR 48840). In
the proposed rule, FDA requested comments on implementing regulations
for the Federal Food, Drug, and Cosmetic Act (the act) entitled ``Index
of Legally Marketed Unapproved New Animal Drugs for Minor Species.''
The agency is taking this action in response to requests for an
extension to allow interested persons additional time to submit
comments.
DATES: Submit written or electronic comments on the proposed rule by
December 20, 2006. Submit comments
[[Page 57893]]
regarding information collection by December 20, 2006, to the Office of
Management and Budget (OMB) (see ADDRESSES).
ADDRESSES: You may submit comments, identified by [Docket No. 2006N-
0067 and RIN number 0910-AF67], by any of the following methods:
Electronic Submissions
Submit electronic comments in the following ways:
Federal eRulemaking Portal: http://frwebgate.access.gpo.gov/cgi-bin/leaving.cgi?from=leavingFR.html&log=linklog&to=http://www.regulations.gov.
Follow the instructions for submitting comments.
Agency Web site: http://frwebgate.access.gpo.gov/cgi-bin/leaving.cgi?from=leavingFR.html&log=linklog&to=http://www.fda.gov/dockets/ecomments.
Follow the instructions for submitting comments on the agency Web site.
Written Submissions
Submit written submissions in the following ways:
FAX: 301-827-6870.
Mail/Hand delivery/Courier [For paper, disk, or CD-ROM
submissions]: Division of Dockets Management (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852.
To ensure more timely processing of comments, FDA is no longer
accepting comments submitted to the agency by e-mail. FDA encourages
you to continue to submit electronic comments by using the Federal
eRulemaking Portal or the agency Web site, as described in the
Electronic Submissions portion of this paragraph.
Instructions: All submissions received must include the agency name
and Docket No(s). and Regulatory Information Number (RIN) (if a RIN
number has been assigned) for this rulemaking. All comments received
may be posted without change to http://frwebgate.access.gpo.gov/cgi-bin/leaving.cgi?from=leavingFR.html&log=linklog&to=http://www.fda.gov/ohrms/dockets/default.htm
, including any personal information provided. For
additional information on submitting comments, see the ``Comments''
heading of the SUPPLEMENTARY INFORMATION section of this document.
Docket: For access to the docket to read background documents or
comments received, go to http://frwebgate.access.gpo.gov/cgi-bin/leaving.cgi?from=leavingFR.html&log=linklog&to=http://www.fda.gov/ohrms/dockets/default.htm
and insert the docket number(s), found in brackets in the heading of
this document, into the ``Search'' box and follow the prompts and/or go
to the Division of Dockets Management, 5630 Fishers Lane, rm. 1061,
Rockville, MD 20852.
Information Collection Provisions: Submit written comments on the
information collection provisions to the Office of Information and
Regulatory Affairs, Office of Management and Budget (OMB).To ensure
that comments on the information collection are received, OMB
recommends that written comments be faxed to the Office of Information
and Regulatory Affairs, OMB, Attn: FDA Desk Officer, FAX: 202-395-6974.
FOR FURTHER INFORMATION CONTACT: Bernadette Dunham, Center for
Veterinary Medicine (HFV-50), Food and Drug Administration, 7519
Standish Pl., Rockville, MD 20855, 240-276-9090, e-mail:
Bernadette.Dunham@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
I. Background
In the Federal Register of August 22, 2006, FDA published a
proposed rule with a 90-day comment period to request comments on
implementing regulations for the indexing provisions of the Minor Use
and Minor Species Animal Health Act of 2004. Comments on the proposed
rule will inform FDA's rulemaking to establish regulations for the
procedures and criteria for index listing a new animal drug for use in
a minor species.
The agency has received requests for a 30-day extension of the
comment period for the proposed rule. Each request conveyed concern
that the current 90-day comment period does not allow sufficient time
to develop a meaningful or thoughtful response to the proposed rule.
FDA has considered the requests and is extending the comment period
for the proposed rule for 30 days, until December 20, 2006. The agency
believes that a 30-day extension allows adequate time for interested
persons to submit comments without significantly delaying rulemaking on
these important issues.
II. Request for Comments
Interested persons may submit to the Division of Dockets Management
(see ADDRESSES) written or electronic comments on this document. Submit
a single copy of electronic comments or two paper copies of any mailed
comments, except that individuals may submit one paper copy. Comments
are to be identified with the docket number found in brackets in the
heading of this document. Received comments may be seen in the Division
of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday.
Dated: September 25, 2006.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. E6-16208 Filed 9-29-06; 8:45 am]
BILLING CODE 4160-01-S